Business Context and Reporting Period
This Form 8-K Current Report was filed by Akers Biosciences, Inc. on January 9, 2015. The report details corporate governance actions taken by the Board of Directors regarding equity compensation plans and specific share issuances to directors and officers.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan amendments and share issuance details.
Material Changes and Corporate Actions
- Plan Amendment: The Board approved the Amended and Restated 2013 Incentive Stock and Award Plan, increasing the number of authorized shares subject to the plan by 400,000 shares.
- Share Issuance: On January 9, 2015, the Company issued an aggregate of 190,000 shares of restricted common stock to certain directors and officers for services rendered and to be rendered.
- Issuance Breakdown:
- Raymond F. Akers, Jr., PhD: 70,000 shares (issued to the Akers Family Trust).
- Thomas Knox: 50,000 shares.
- Brandon Knox: 35,000 shares.
- Gavin Moran: 35,000 shares.
Conditions, Lock-Up Agreements, and Risks
The issued shares are subject to specific conditions and restrictions:
- Recoupment: Shares are subject to full recoupment by the Company if a Holder is terminated for cause or is not providing services to the Company on January 1, 2017.
- Lock-Up Periods:
- Thomas Knox, Brandon Knox, and Gavin Moran: Restricted from selling shares from January 9, 2015, to January 1, 2017.
- Raymond F. Akers, Jr., PhD (via the Trust): Restricted from selling shares from January 1, 2015, to January 1, 2020.
Investor Verification Checklist
- Verify the full text of the Amended and Restated 2013 Incentive Stock and Award Plan (Exhibit 10.1) for additional terms not summarized here.
- Review the Form of Lock-Up Agreement (Exhibit 10.2) to understand all restrictions on the disposal of shares.
- Confirm the current service status of the named Holders to assess the risk of share recoupment.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.